{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"stage IIIA-N2 EGFR-mutated NSCLC","name":"ANSWER","nct_id":"NCT04455594","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=answer-nct04455594. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ANSWER","arms":[{"description":"Almonertinib 110mg QD","label":"Almonertinib","type":"EXPERIMENTAL"},{"description":"Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles","label":"Investigator-choice therapy (Erlotinib or Chemotherapy)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-10","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer Stage IIIA"],"enrollment":{"count":168,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Almonertinib","otherNames":["HS-10296"],"type":"DRUG"},{"name":"Erlotinib","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2020-07-02","lead_sponsor":"The First Affiliated Hospital of Guangzhou Medical University","official_title":"Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC: a Multicenter, Open-label, Phase II Randomized Controlled Trial","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"From date of randomization to an average of 6 weeks after the first dose"}],"references":[],"start_date":{"date":"2020-10","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC","url":"https://clinicaltrials.gov/study/NCT04455594"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/answer-nct04455594"}